The Investment Column: Inventive demerger gives BTG a lift
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.IN DECIDING to spin off Torotrak, its revolutionary transmission system, BTG is following a highly profitable tradition. Previously, privatised companies as diverse as National Grid and British Aerospace have done wonders for shareholders by demerging promising, but separate, businesses on to the stock market.
Torotrak highlights the value BTG can squeeze out of technologies. A business on which the group has spent pounds 12m over 10 years will float with a value of close to pounds 400m after raising pounds 50m of new money. Given that the system is already being worked on by 12 of the world's leading car makers, there is plenty of future promise for shareholders.
But what is the rest of BTG worth? It will be left with more than 1,000 other technologies or inventions, including a host of biotech treatments already on the books of drug giants such as SmithKline and Zeneca. Not to mention a revolutionary artificial hip-cup, disposable contact lenses and an electronic bar-coding system. New revenue is rocketing and BTG should make a profit early in the next century.
Still, valuing this collection of inventions is tough. Kleinwort Benson, BTG's broker, reckons the existing portfolio is worth anything from pounds 300m to pounds 2bn, and Torotrak accounts for 55 per cent of the total. It is a wide range, but as yesterday's 34p share-price rise to 736.5p suggested, the demerger lifts the probable value of the portfolio. And the shares still look a better bet than other biotech and "future value" companies. Hold tight for the next millennium.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments